Skip to main content
Boyu Hu
( out of 101 reviews )

Boyu Hu, MD

Languages spoken: English

Clinical Locations

Huntsman Cancer Institute - Cancer Research North

Clinic 2D/E, BMT/Hematology
Salt Lake City
801-213-3718
  • Dr. Boyu Hu is the Director of Lymphoma and Chronic Lymphocytic Leukemia (CLL) within the Division of Hematology and Hematologic Malignancies. He specializes in treating and performing research in patients with lymphoid malignancies (i.e. non-Hodgkin lymphoma and Hodgkin lymphoma) and CLL. He is primarily a clinical researcher and has been the principal investigator on over 20 phase I, II and III clinical trials investigating novel treatments and combination therapies for patients diagnosed with lymphoma and CLL. His contributions to the field have led to the direct FDA approval and development of targeted therapies, bispecific antibodies and chimeric antigen receptor T-cell therapies. Nationally, he serves as a member and the Huntsman Cancer Institute representative for the National Comprehensive Cancer Network B-cell Lymphoma Guidelines committee. Furthermore, he is an active participant within the Southwest Oncology Group and the National Clinical Trials Network. He is currently the co-chair and national principal investigator for AHOD2131, which is a randomized phase III clinical trial investigating the incorporation of novel immuno-oncology agents for the treatment of early stage Hodgkin lymphoma.

    Board Certification

    American Board of Internal Medicine
    American Board of Internal Medicine (Sub: Hematology)
    American Board of Internal Medicine (Sub: Medical Oncology)

    Patient Rating

    4.9 /5
    ( out of 101 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    April 05, 2024
    HUNTSMAN CANCER CENTER

    I feel extremely lucky to have the good fortunate to have the care and attention of Dr Hu and his incredible team. He has presented me with two incredible opportunities to thoughtfully manage my CLL diagnosis and enhance my overall wellbeing. I am grateful for his knowable care, concern and kindness.

    March 31, 2024
    HUNTSMAN CANCER CENTER

    Knowledgeable, kind, not rushed,good at explaining disease details.

    March 24, 2024
    HUNTSMAN CANCER CENTER

    Choosing Dr. Hu as my oncologist was the best decision I could have made. Every visit he demonstrates excellent care. He listens, explains everything clearly and has made my cancer journey less scary and has given me the tools I needed within myself to get through it. I have always felt he genuinely cares about me and my progress.

    March 24, 2024
    HUNTSMAN CANCER CENTER

    Very caring and informative.

    March 21, 2024
    HUNTSMAN CANCER CENTER

    Dr. Hu has been caring for me for over a year now. I can't thank him enough for his care, advice, and support.

    March 21, 2024
    HUNTSMAN CANCER CENTER

    Dr. Hu and his team have been extremely great to work with. They are courteous, informative, transparent, and great at answering questions and putting them into terms that I could understand. I would highly recommend them.

    March 16, 2024
    HUNTSMAN CANCER CENTER

    Dr.Hu is very nolagable in his field

    March 03, 2024
    HUNTSMAN CANCER CENTER

    Excellent care giver

    February 29, 2024
    HUNTSMAN CANCER CENTER

    I count him as more than just my doctor he has become my friend. If anyone needs some to fight their cancer he is it.

  • Dr. Boyu Hu is the Director of Lymphoma and Chronic Lymphocytic Leukemia (CLL) within the Division of Hematology and Hematologic Malignancies. He specializes in treating and performing research in patients with lymphoid malignancies (i.e. non-Hodgkin lymphoma and Hodgkin lymphoma) and CLL. He is primarily a clinical researcher and has been the principal investigator on over 20 phase I, II and III clinical trials investigating novel treatments and combination therapies for patients diagnosed with lymphoma and CLL. His contributions to the field have led to the direct FDA approval and development of targeted therapies, bispecific antibodies and chimeric antigen receptor T-cell therapies. Nationally, he serves as a member and the Huntsman Cancer Institute representative for the National Comprehensive Cancer Network B-cell Lymphoma Guidelines committee. Furthermore, he is an active participant within the Southwest Oncology Group and the National Clinical Trials Network. He is currently the co-chair and national principal investigator for AHOD2131, which is a randomized phase III clinical trial investigating the incorporation of novel immuno-oncology agents for the treatment of early stage Hodgkin lymphoma.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Primary
    Academic Divisions Hematology
    Board Certification
    American Board of Internal Medicine
    American Board of Internal Medicine (Sub: Hematology)
    American Board of Internal Medicine (Sub: Medical Oncology)

    Education history

    Fellowship Hematology/Oncology - University of Texas MD Anderson Cancer Center Fellow
    Internal Medicine - Hospital of the University of Pennsylvania Resident
    Internship Internal Medicine - Hospital of the University of Pennsylvania Intern
    Medicine - Case Western Reserve University School of Medicine M.D.
    Undergraduate Duke University B.S.

    Selected Publications

    Journal Article

    1. Azim A, Hu B, Gilligan S, Sarwal A, Hartsell S, Pandya V, Raphael KL (2023). How I Evaluate a High Anion Gap Metabolic Acidosis. Clin J Am Soc Nephrol. (Read full article)
    2. Bowers JT, Anna J, Bair SM, Annunzio K, Epperla N, Pullukkara JJ, Gaballa S, Spinner MA, Li S, Messmer MR, Nguyen J, Ayers EC, Wagner CB, Hu B, Di M, Huntington SF, Furqan F, Shah NN, Chen C, Ballard HJ, Hughes ME, Chong EA, Nasta SD, Barta SK, Landsburg DJ, Svoboda J (2023). Brentuximab vedotin plus AVD for Hodgkin lymphoma: incidence and management of peripheral neuropathy in a multisite cohort. Blood Adv, 7(21), 6630-6638. (Read full article)
    3. Wagner CB, Boucher K, Nedved A, Micallef IN, Desai S, Hatic H, Goyal G, Zacholski E, Fegley A, Sigmund AM, Bond DA, Samuels C, Kamdar MK, Ba Aqeel S, Torka P, MacDougall K, Borogovac A, Rajeeve S, Sundaram S, Fedak K, Modi D, Travers E, Ayyappan S, Chilakamarri N, Brem EA, Ermann DA, Fitzgerald LA, Hu B, Stephens DM, Shah H (2023). Effect of cumulative dose of brentuximab vedotin maintenance in relapsed/refractory classical Hodgkin lymphoma after autologous stem cell transplant: an analysis of real-world outcomes. Haematologica, 108(11), 3025-3032. (Read full article)
    4. Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Andreadis B, Bartlett NL, Budde LE, Caimi PF, Chang JE, Christian B, DeVos S, Dholaria B, Fayad LE, Habermann TM, Hamid MS, Hernandez-Ilizaliturri F, Hu B, Kaminski MS, Karimi Y, Kelsey CR, King R, Krivacic S, LaCasce AS, Lim M, Messmer M, Narkhede M, Rabinovitch R, Ramakrishnan P, Reid E, Roberts KB, Saeed H, Smith SD, Svoboda J, Swinnen LJ, Tuscano J, Vose JM, Dwyer MA, Sundar H (2023). NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023. J Natl Compr Canc Netw, 21(11), 1118-1131. (Read full article)
    5. Ermann DA, Vardell VA, Shah H, Fitzgerald L, Tao R, Gaffney DK, Stephens DM, Hu B (2023). Survival Outcomes of Limited-Stage Diffuse Large B-Cell Lymphoma Treated With Radiation Therapy. Clin Lymphoma Myeloma Leuk, 24(2), 94-104.e6. (Read full article)
    6. Vardell VA, Ermann DA, Fitzgerald LA, Shah HR, Hu B, Stephens DM (2023). Influence of racial and ethnic identity on overall survival in patients with chronic lymphocytic leukemia. Am J Hematol, 98(7), E172-E174.
    7. Fenlon JB, Hutten RJ, Johnson SB, Hu B, Shah H, Stephens DM, Maity A, Gaffney DK, Tao R (2022). Evaluating patterns of care for early-stage low-grade follicular lymphoma in the rituximab era. Leukemia & Lymphoma, 64(2), 356-363. (Read full article)
    8. Parson MW, Rock C, Chipman JJ, Shah HR, Hu B, Stephens DM, Tao R, Tward JD, Gaffney DK (2023). Secondary malignancies in non-Hodgkin lymphoma survivors: 40 years of follow-up assessed by treatment modality. Cancer Medicine, 12(3), 2624-2636.
    9. Parsons MW, Rock C, Chipman JJ, Shah HR, Hu B, Stephens DM, Tao R, Tward JD, Gaffney DK (2022). Secondary malignancies in non-Hodgkin lymphoma survivors: 40 years of follow-up assessed by treatment modality. Cancer Med, 12(3), 2624-2636. (Read full article)
    10. Stephens DM, Huang Y, Ruppert AS, Walker JS, Canfield D, Cempre CB, Fu Q, Baker S, Hu B, Shah H, Vadeboncoeur R, Rogers KA, Bhat S, Jaglowski SM, Lockman H, Lapalombella R, Byrd JC, Woyach JA (2021). Selinexor Combined with Ibrutinib Demonstrates Tolerability and Safety in Advanced B-Cell Malignancies: A Phase I Study. Clin Cancer Res, 28(15), 3242-3247. (Read full article)
    11. Rock CB, Chipman JJ, Parsons MW, Weil CR, Hutten RJ, Tao R, Tward JD, Shah HR, Hu B, Stephens DM, Gaffney DK (2022). Second Primary Malignancies in Diffuse Large B-cell Lymphoma Survivors with 40 Years of Follow Up: Influence of Chemotherapy and Radiation Therapy. Adv Radiat Oncol, 7(6), 101035. (Read full article)
    12. Dave H, Terpilowski M, Mai M, Toner K, Grant M, Stanovich M, Lazarski C, Shibli A, Maglo P, Hog F, Schore R, Glenn M, Hu B, Hanley P, Ambinder R, Bollard CM (2021). Tumor associated antigen specific T cells with nivolumab are safe and persist in vivo in rel/ref Hodgkin Lymphoma. Blood Adv, 6, 473-485. (Read full article)
    13. Feusier JE, Madsen MJ, Avery BJ, Williams JA, Stephens DM, Hu B, Osman AEG, Glenn MJ, Camp NJ (2021). Shared genomic segment analysis in a large high-risk chronic lymphocytic leukemia pedigree implicates CXCR4 in inherited risk. J Transl Genet Genom, 5, 189-199. (Read full article)
    14. Hu B, Patel KP, Chen HC, Wang X, Luthra R, Routbort MJ, Kangal-Shamanna R, Medeiros LJ, Yin CC, Zuo Z, Ok CY, Loghavi S, Tang G, Tambaro FP, Thompson, P, Burger J, Jain N, Ferrajoli A, Estrov Z, Keating MJ, Wierda WG (2019). Routine sequencing in CLL has prognostic implications and provides new insight into pathogenesis and targeted treatments. Br J Haematol, 185(5), 852-864.
    15. Hu B, Patel KP, Chen HC, Wang X, Luthra R, Routbort MJ, Kangal-Shamanna R, Medeiros LJ, Yin CC, Zuo Z, Ok CY, Loghavi S, Tang G, Tambaro FP, Thompson, P, Burger J, Jain N, Ferrajoli A, Bose P, Estov Z, Keating M, Wierda WG (2019). Association of gene mutations with time-to-first treatment in 384 treatment-naive chronic lymphocytic leukaemia patients. Br J Haematol, 187(3), 307-318.
    16. Hu B, Takahashi K, et al (2018). Clinical Implications of Cancer Gene Mutations in Patients with Chronic Lymphocytic Leukemia Treated with Lenalidomide. Blood, 131(16), 1820-32.
    17. Hu Z, Hu B, Collins JF (2007). Prediction of synergistic transcription factors by function conservation. Genome Biol, 8(12), R257. (Read full article)

    Review

    1. Hu B, Oki Y (2018). Novel Immunotherapy Options for Extranodal NK/T-cell Lymphoma. [Review]. Front Oncol, 8(139).

    Case Report

    1. Gociman S, Baron K, Hu B, Zussman J, Madigan LM (2022). Blistering Lesions Associated With Loncastuximab Tesirine. JAMA Dermatol, 158(7), 831-832. (Read full article)
    2. Hu B, Patel JL, Tao R, Cannon RB, Monroe M, Goyal G (2022). Near Complete Response to Trametinib Treatment in Histiocytic Sarcoma Harboring a Somatic KRAS Mutation. J Natl Compr Canc Netw, 20(6), 1-4. (Read full article)

    Letter

    1. Vardell VA, Ermann DA, Fitzgerald L, Shah H, Hu B, Stephens DM (2024). T-cell prolymphocytic leukemia: Epidemiology and survival trends in the era of novel treatments. [Letter to the editor]. Am J Hematol, 99(3), 494-496. (Read full article)
    2. Vardell VA, Ermann DA, Fitzgerald LA, Shah HR, Hu B, Stephens DM (2023). Influence of racial and ethnic identity on overall survival in patients with chronic lymphocytic leukemia. [Letter to the editor]. Am J Hematol, 98(7), E172-E174. (Read full article)
  • News & Podcasts